Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

However, analysts from Cantor Fitzgerald, Oppenheimer, and JPMorgan were among those to reiterate their buy-equivalent ratings on Regeneron (NASDAQ:REGN) despite the trial setback. “We do still ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

JPMorgan Reiterates 2025 Net Interest Income Forecast. Wall Street Awaits Any Word on Dimon Succession Plans. The bank says it is â positioned to deliver strong returns' in the face of ...

Regeneron Pharmaceuticals (REGN ... declined as the maker of contact lenses cut its full-year organic growth outlook and JPMorgan downgraded the stock and lowered its price target on concerns about ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (BMV:REGN) from Overweight to Equal-Weight. Jpmorgan Chase holds 5,658K shares representing ...

There are 2,377 funds or institutions reporting positions in Regeneron Pharmaceuticals ... last three months by 0.93% to 113,247K shares. Jpmorgan Chase holds 5,658K shares representing 5.45% ...